Introduction
============

Graves\' disease (GD) is a common autoimmune disease, and oral antithyroid agents remain the first line of treatment in Japan and European countries ([@B1]-[@B3]), although radioactive iodine is currently the primary treatment in the US. Among the available antithyroid agents, thiamazole (MMI) is the most widely used agent in Japan. Although MMI has a better safety profile than propylthiouracil (PTU) ([@B4]), the adverse effects of MMI range from mild events (e.g., skin eruptions) to life-threatening events (e.g., agranulocytosis and severe hepatitis). Musculoskeletal complaints are not rare among patients with thyroid disorders and are also described as adverse effects of antithyroid drugs ([@B5]). Furthermore, vasculitis can manifest as arthritis and has been described since the 1950s as a major toxic reaction to antithyroid agents ([@B6]), and attention is currently focused on anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) syndrome. However, the focus on this syndrome has obscured the fact that non-vasculitis arthritis can also be induced by antithyroid drugs, defined as antithyroid arthritis syndrome ([@B5]). Thus, there are few detailed reports regarding antithyroid arthritis syndrome, especially in the context of differentiating it from antithyroid agent-induced vasculitis.

We report the case of a 38-year-old Japanese woman who experienced severe migratory polyarthritis after receiving MMI. We excluded the possibility of reactive arthritis and MMI-induced vasculitis syndrome and observed that the patient\'s symptoms promptly resolved after withdrawing the MMI treatment. This case and the accompanying literature review highlight the importance of antithyroid arthritis syndrome when diagnosing patients who develop arthritis after receiving antithyroid agents.

Case Report
===========

A 38-year-old Japanese woman was referred to our hospital with symptoms of a goiter. She had previously been healthy, with no history of delivery, allergies, or joint symptoms. There was no family history of thyroid or collagen diseases. A physical examination revealed that the patient was afebrile, had a blood pressure of 140/71 mmHg, and had a pulse rate of 99 beats/min with regular rhythm. Her height was 160 cm, and her weight was 54.4 kg. We observed that her thyroid gland was diffusely enlarged and that she exhibited fine hand tremors, although an examination using an exophthalmometer did not reveal exophthalmos.

The laboratory results included hemoglobin levels of 12.0 g/dL, a total white blood cell count of 3,800 /μL, and a platelet count of 29.3×10^3^/μL. There was no proteinuria or hematuria, and her levels of C-reactive protein (CRP), aspartate aminotransferase, and alanine aminotransferase were within the normal ranges. However, her alkaline phosphatase levels were slightly elevated (479 U/L), and we found markedly elevated levels of free serum thyroxine (FT~4~; 9.44 ng/dL) and free triiodothyronine (FT~3~; \>30 pg/mL). The patient\'s thyroid stimulating hormone (TSH) levels were suppressed (0.02 μIU/mL), and a third-generation TSH receptor antibody test revealed positive results (190 IU/L). We also observed positive results for antithyroid peroxidase antibody (493 IU/mL) and antithyroglobulin antibody (73 IU/mL). Homogenous and diffuse uptake was observed in both lobes using thyroid scintigraphy with ^99m^Tc pertechnetate. Based on these findings, we diagnosed the patient with GD and started treatment using MMI at a dose of 45 mg/day. We also added potassium iodide (50 mg/day) and propranolol hydrochloride (30 mg/day) because of the severe hyperthyroidism and tachycardia.

Three weeks later, the patient presented with a fever and arthralgia, particularly in the right ankle, which prevented her from walking. Five days prior, she had experienced spontaneous progressive arthralgia that started in the metacarpophalangeal joint of her right thumb and then migrated to the left thumb, thoracic vertebrae, and right ankle. The pain in the affected joints worsened each day and eventually became intolerable. She also complained of a low-grade fever at night (37.5-37.9℃), and a physical examination revealed that her right lateral malleolus was mildly swollen, slightly flushed, warm, and remarkably tender ([Fig. 1](#g001){ref-type="fig"}). It also revealed a tender right Achilles\' tendon and middle thoracic vertebrae, and tender and slightly swollen carpometacarpal and metacarpophalangeal joints in both thumbs. The right ankle\'s motion was limited by the severe pain, although there were no signs of skin eruptions, facial erythema, or photosensitivity, Raynaud\'s phenomenon, suggesting lupus-like syndrome. The patient\'s superficial lymph nodes were not palpable, and she did not have an enlarged liver or spleen.

![The patient's left foot (A) and right foot (B).](1349-7235-55-3627-g001){#g001}

At that time, laboratory testing ([Table 1](#t001){ref-type="table"}) revealed an elevated erythrocyte sedimentation rate, CRP levels, and IL-6 levels, which indicated moderate inflammation. The serum levels of FT~3~, FT~4~, and TSH were 10.7 pg/mL, 3.18 ng/dL, and 0.02 μIU/mL, respectively, which indicated an improved thyroid function. We performed an orthopedic examination, although foot radiography revealed no specific findings. Magnetic resonance imaging of the right ankle also revealed no abnormalities, with the exception of a non-specific signal at the talus ([Fig. 2](#g002){ref-type="fig"}).

###### 

Laboratory Findings at the Presentation with Arthritis.

  ---------------------------------- --------------- ------------------------- ------------------------------------ --------------
  **Urinalysis**                                     **Serological tests**                                          
  Protein                            (-)                                       IgG                                  1,073 mg/dL
  Blood                              (-)                                       IgA                                  424 mg/dL
  **Complete Blood Count**                           IgM                       74 mg/dL                             
  ESR                                62 mm/hr                                  IgE                                  101 IU/mL
  Peripheral blood                                                             IgD                                  1.5 mg/dL
  WBC                                7,200/μL                                  CH~50~                               85 U/mL
  Segmented                          64.5%                                     RF                                   3 U/mL
  Stab                               7.5%                                      Anti-CCP antibody                    \< 0.06 U/mL
  Lymph                              19.5%                                     MPO-ANCA                             \< 1.0 EU
  Bas                                0.0%                                      PR3-ANCA                             \< 1.0 EU
  Eo                                 0.0%                                      ANA                                  \< ×40
  Mon                                8.5%                                      LE test                              (-)
  RBC                                448×10^4^/μL                              Anti-DNA antibody                    \< 2.0 IU/mL
  Hemoglobin                         11.9 g/dL                                 Anti-Sm antibody                     \< 0.5 U/mL
  Platelet                           30.8×10^4^/μL                             Anti-U1RNP antibody                  \< 0.5 U/mL
  **Blood Chemistry and Hormones**                   Anti-SCL-70 antibody      (-)                                  
  Total protein                      6.9 g/dL                                  Anti-Jo-1 antibody                   (-)
  Albumin                            4.2 g/dL                                  Anti-cardiolipin antibody            \< 8 U/mL
  AST                                12 IU/L                                   Anti-GAD antibody                    \< 0.3 U/mL
  ALT                                11 IU/L                                   ASLO                                 203 IU/mL
  ALP                                581 IU/L                                  **Stool Culture**                    
  LDH                                160 IU/L                                  *Yersenia*                           (-)
  CK                                 31 U/L                                    *Salmonella*                         (-)
  Postprandial glucose               126 mg/dL                                 *Shigella*                           (-)
  BUN                                8 mg/dL                                   *Campylobacter*                      (-)
  Creatinine                         0.31 mg/dL                                **Urine Tests for Microorganisms**   
  Na                                 139 mEq/L                                 *C. trachomatis*                     (-)
  K                                  4.1 mEq/L                                 *N. gonorrhea*                       (-)
  Cl                                 105 mEq/L                                 ***Mycoplasma antibodies***          (-)
  CRP                                2.33 mg/dL                                **Viral Tests**                      
  IL-6                               13 pg/mL                                  HBs antigen                          0.1 COI
  TSH                                0.02 μIU/mL                               HCV antibody                         0.1 COI
  FT~4~                              3.18 ng/dL                                HA antibody (EIA)                    0.28 S/CO
  FT~3~                              10.7 pg/mL                                IgM-HA antibody                      0.10 S/CO
  **Coagulation Study**                              Parvovirus B19 antibody                                        
  PT                                 94%                                       IgG (reference: \<0.80)              3.23
  APTT                               30.2 sec                                  IgM (reference: \<0.80)              0.26
  Fibrinogen                         314 mg/dL                                                                      
  ---------------------------------- --------------- ------------------------- ------------------------------------ --------------

![Magnetic resonance imaging of the right foot (short tau inversion recovery-T1). The arrow indicates a non-specific signal at the talus.](1349-7235-55-3627-g002){#g002}

Although she did not have any diarrheal symptoms that indicated enterocolitis, a stool culture was performed to identify any bacteria that might have caused reactive arthritis. The results were negative for *Yersenia*, *Salmonella*, *Shigella*, and *Campylobacter* species. Based on her age, we also considered that she might have reactive arthritis that was secondary to *Neisseria* or *Chlamydia* infection, although transcription-mediated amplification tests revealed negative results for *Chlamydia trachomatis* and *Neisseria gonorrhoeae*. We did not detect any antibodies to *Mycoplasma* (using the complement fixation and passive agglutination tests), and there was no increase in the paired sera titers after two weeks. Therefore, we considered that the patient had reactive arthritis that was secondary to a viral infection, although we did not detect hepatitis virus antigens or antibodies. The titers of human parvovirus B19-specific IgG were high, although the IgM titers were within the normal range, and neither antibody exhibited any increase in the paired sera titers after two weeks.

Next, we considered the possibility of autoimmune diseases or antithyroid drug-induced AAV. However, we did not detect any autoantibodies, including myeloperoxidase (MPO)-ANCAs and proteinase 3 (PR3)-ANCAs. We therefore excluded idiopathic collagen diseases and drug-induced AAV. We performed drug lymphocyte stimulation tests (DSLTs) with ^3^H-thymidine incorporation and found that the stimulation index for MMI was high (26.9, positive: \>1.8). Therefore, as we suspected an adverse reaction to the MMI treatment, we substituted PTU treatment at 450 mg/day. The same dosages of propranolol hydrochloride and potassium iodide were continued, and loxoprofen sodium hydrate was started for the arthralgia.

The patient\'s symptoms promptly resolved the same day after withdrawing the MMI and starting loxoprofen. In addition, the pain and swelling in the affected joints disappeared after one week (except for in the right ankle), and we stopped treating the patient using loxoprofen sodium hydrate. A follow-up evaluation at two weeks after discontinuing the MMI revealed that the right ankle appeared normal, with the full range of motion restore and no swelling, redness, or pain. We also observed that the inflammatory indexes were almost normalized (CRP: 0.17 mg/dL, IL-6: 6 pg/mL). At that time, her FT~3~, FT~4~, and THS levels were 7.7 pg/mL, 2.56 ng/dL, and 0.02 μIU/mL, respectively; thus, we continued the PTU and tapered and stopped the potassium iodide. Follow-up magnetic resonance imaging at three months revealed no significant changes, although the signal at the right talus persisted, despite the improvement in the patient\'s symptoms. We therefore deemed that this signal was not clinically significant. The patient has continued to receive PTU for \>1 year and has a normalized thyroid status, with no recurrent joint symptoms or toxic reactions experienced during the follow-up period.

Discussion
==========

Musculoskeletal complaints are not rare in cases of thyroid disorders and are often unnoticed or unremarked. In the present case, we considered the episode of multi-joint pain to be polyarthritis, rather than arthralgia, because of the objective joint swelling and elevated values of inflammation markers (e.g., CRP and IL-6), which indicated the existence of synovitis. In this context, arthritis may occur in association with a wide variety of diseases, and bacterial or viral infections can cause either acute or chronic arthritis ([@B7]). However, the patient in the present case did not exhibit any symptoms that suggested infection, and the test results were negative for various infectious diseases and antibody titers. Autoimmune diseases should also be included in the differential diagnosis of arthritis, although our laboratory test results were negative for autoimmune diseases. Given that the arthritis in the present case developed shortly after the patient started receiving MMI, and the symptoms resolved shortly after discontinuing this drug, we concluded that the symptoms were induced by the MMI treatment ([@B8]).

Vasculitis is a major toxic reaction that is induced by antithyroid treatment, and this condition may manifest as arthritis ([@B5]). Drug-induced vasculitis is commonly associated with ANCA-positivity ([@B9], [@B10]), especially in patients who have received antithyroid agents ([@B11]), although the exact positivity rate is unclear, because the diagnostic criteria for drug-induced vasculitis include ANCA-positivity in many reports ([@B12], [@B13]). Pillinger et al. described 23 cases of PTU-related vasculitis ([@B14]) and found positive results for ANCAs in all 20 cases that underwent ANCA testing. The first case was reported in 1992 ([@B15]), and \>100 cases of antithyroid agent-induced AAV have currently been reported ([@B11]); these cases are especially common among Asian patients treated using PTU ([@B16]). The spectrum of its manifestations is broad and ranges from non-specific syndromes to single-organ involvement and life-threatening vasculitis, with arthralgia and arthritis being among the most frequent symptoms at the onset of AAV ([@B11]). Most patients have perinuclear (p)-ANCAs, with a majority of these patients having MPO-ANCAs ([@B5]).

Drug-induced lupus can also manifest as arthritis, and clinical and serological results that are consistent with lupus erythematosus have been observed in some patients who were treated using antithyroid agents ([@B17]). Interestingly, many researchers insist that it is irrelevant to distinguish between antithyroid agent-induced lupus-like syndrome and AAV ([@B11]), although other researchers make a clear distinction between these conditions ([@B18]). Furthermore, Yamada et al. described 22 cases of PTU-induced lupus-like syndrome from before 2001 (including their ANCA-positive case) ([@B17]). [Table 2](#t002){ref-type="table"} shows the results of a literature review regarding ANCAs and antithyroid agent-induced lupus-like syndrome, which has been reported in association with all kinds of anti-thyroid agents that are currently in use. All 18 cases that were examined for ANCAs had positive results, especially for MPO-ANCAs or p-ANCAs. This result appears to support the previous findings that drug-induced lupus has serological features that are different from those of idiopathic systemic lupus erythematosus (only 15-20% of the patients are ANCA-positive) ([@B19]) and that anti-thyroid agent-induced lupus-like syndrome cannot be clearly distinguished from AAV ([@B20]). Furthermore, specific types of antithyroid agent-induced AAV have been reported, such as Wegener\'s granulomatosis ([@B14]), Henoch-Schönlein purpura ([@B21]), Churg-Strauss syndrome ([@B22]), and bilateral sensorineural hearing loss ([@B23]). Thus, it has been hypothesized that antithyroid drugs, especially PTU, can react with MPO and form reactive intermediates that promote autoimmune inflammation ([@B24]).

###### 

Reports Regarding Antithyroid Drug-induced Lupus-like Syndrome that Examined Anti-neutrophil Cytoplasmic Antibodies.

  Reference   ATD   MPO (p) -ANCA           PR3 (c) -ANCA   ANA   Anti-dsDNA antibody   Joint symptoms
  ----------- ----- --------------- ------- --------------- ----- --------------------- ----------------
  \(33\)      PTU                   (+)\*                   (+)                         
  \(34\)      PTU                   (+)\*                   (+)                         (+)
  \(35\)      MMI   (+)                                     (+)   (+)                   
  \(36\)      PTU   (+)                     (±)             (+)   (+)                   (+)
  \(17\)      PTU   (+)                     (-)             (+)   (+)                   (+)
  \(37\)      MMI   (+)                     (-)             (+)   (+)                   
  \(38\)      MMI   (+)                     (-)             (+)   (+)                   (-)
  \(18\)      PTU   (+)                     (-)             (+)                         (+)
              PTU   (+)                     (-)             (+)   (-)                   (+)
              PTU   (+)                                     (+)                         (+)
  \(13\)      PTU   (+)                     (-)             (+)   (+)                   (+)
              PTU   (+)                     (-)             (+)   (-)                   (+)
              PTU   (+)                     (-)             (+)   (-)                   (+)
              PTU   (+)                     (-)             (+)   (-)                   (+)
  \(39\)      PTU   (+)                     (+)             (+)   (-)                   (+)
  \(40\)      MMI                   (+)\*                   (+)   (+)                   (+)
  \(41\)      CBZ   (+)                     (-)             (+)   (+)                   
  \(42\)      PTU   (+)                     (+)             (+)   (+)                   (+)

ATD: antithyroid drug, PTU: propylthiouracil, MMI: thiamazole, CBZ: carbimazole, \*: ANCA subtypes not known. Blank line indicates \"not described\"

Based on the absence of ANCAs and most vasculitis symptoms (e.g., nephritis, skin lesions, and systemic symptoms), the present case appears to be antithyroid arthritis syndrome, rather than vasculitis or lupus-like syndrome as mentioned above. Antithyroid arthritis syndrome has been recognized for longer than 60 years and was initially described as a rare toxic reaction to antithyroid agents. Williams et al. described three cases of PTU-associated arthritis in 1946, and one of those cases could be considered antithyroid arthritis syndrome ([@B25]). Although this syndrome typically develops as a minor reaction to antithyroid agents, erythema and swelling of the joints may be present (as in the current case) and may indicate a more severe migratory polyarthritis ([@B5]). The arthralgia is continuously progressive, although it can occasionally be intermittent over a prolonged course (e.g., 10 years) ([@B26]). However, antithyroid arthritis syndrome has been poorly characterized and is underappreciated ([@B27]), especially regarding its discrimination from vasculitis-related arthritis.

[Table 3](#t003){ref-type="table"} shows the findings from a literature review of the reports regarding this syndrome, which predominantly affects female patients, reflects the epidemiology of GD, occurs within 1 month after starting the antithyroid agent, and exhibits inflammatory signs, such as fever, leukocytosis, and elevated CRP levels. However, many of these reports, especially the older reports, lack information regarding ANCA status. Nevertheless, ANCAs were confirmed to be absent in the six latest reports (including the present case), which indicate that antithyroid arthritis syndrome has serological characteristics (e.g., negative for ANCAs) that are different from those of antithyroid agent-induced vasculitis and lupus-like syndrome.

###### 

Literature Review of Antithyroid Arthritis Syndrome.

  Reference       Age/sex   Drug      Latency   Fever   Skin Eruption   CRP (mg/dL)   ESR (mm/hr)   WBC (/μL)   MPO (P) -ANCA   PR3 (C) -ANCA   ANA   
  --------------- --------- --------- --------- ------- --------------- ------------- ------------- ----------- --------------- --------------- ----- -----
  \(25\)          30/F      PTU       10 dy     (+)     (+)                                         3,800                                             
  \(6\)           50/M      MMI       5.5 wk    (+)     (-)                           40            13,000                                            
                  25/F      MMI       4 mo      (+)     (+)                                         3,600                                             
                  45/F      MMI       1 mo              (+)                                         10,000                                            
                  31/F      MMI       4 wk      (+)     (+)                           30            7,200                                             
  \(43\)          26/F      MMI       15 dy     (+)                     (3+)          54            10,000                                      (-)   
  \(44\)          28/F      MMI       3 wk      (+)     (+)             WNR           23            10,500                                      (-)   
                  63/F      MMI       2 wk                                            37            6,400                                             
                  47/F      PTU       3 wk      (+)                                   48            4,500                                             
  \(30\)          12/F      PTU/MMI   18 mo             (+)                           30            WNR                                         (+)   
                  11/F      PTU/MMI   22 mo                             (+)           WNR           39          WNR                                   (+)
  \(28\)          25/F      MMI/PTU   7 wk                                                                                                            
  \(45\)          42/F      MMI       4 wk      (+)     (-)             WNR           WNR           WNR                                         (-)   
  \(26\)          45/F      PTU       \>10 yr   (+)                     elevated      WNR           WNR                                         (-)   
  \(29\)          37/F      MMI       1 wk      (-)     (-)                                                                                     (+)   
  \(46\)          69/F      MMI       5 wk                                            60            11,600                                            (-)
  \(47\)          50/M      CBZ       1 wk      (+)     (+)             18.7          48            WNR                                               
  \(48\)          15/F      MMI       3 wk      (-)     (+)             12                          8,600       (-)             (-)             (+)   
  \(49\)          15/F      MMI       24 dy     (+)     (+)             3.41                        8,600       (-)             (-)                   
                  11/F      MMI       28 dy     (+)     (+)             2.41          64            6,800       (-)                             (+)   
  \(27\)          40/F      MMI       2-3 mo                            WNR           WNR                       (-)             (-)             (+)   
  \(50\)          13/F      MMI       2 wk      (-)     (+)             21                                      (-)             (-)             (-)   
  Present Study   38/F      MMI       2 wk      (+)     (-)             2.33          62            7,200       (-)             (-)             (-)   

PTU: propylthiouracil, MMI: thiamazole, CBZ: carbimazole, WNR: within normal range. Blank line indicates \"not described\"

Antithyroid arthritis syndrome usually resolves without any sequelae within several weeks after the cessation of the causative drug ([@B28]), and steroids have occasionally been administered without any evidence of efficacy ([@B29]). Alternative antithyroid agents can occasionally be used without symptom recurrence (as in the present case), although cross-reactivity has also been reported ([@B28], [@B30]). Little is known regarding the mechanism of this syndrome, although some researchers insist that the complex of copper and the antithyroid agent affects glutathione metabolism and induces the release of interleukins, which can cause synovial inflammation ([@B31]). Alternatively, other researchers claim that the binding of the antithyroid agent to macromolecules can induce auto-antibody production, despite the absence of evidence for autoantibody production in this syndrome ([@B32]). Nevertheless, an allergic mechanism may be involved, based on the strongly positive DSLT results for MMI in the present case. Therefore, further studies are needed to evaluate the mechanism of this syndrome.

In conclusion, the present case highlights the importance of recognizing antithyroid arthritis syndrome as an adverse effect of antithyroid agents, which can result in severe migratory polyarthritis. Given the unpredictable and potentially life-threating vasculitis that can be caused by antithyroid agents, it is essential for clinicians to be aware of this condition and to promptly withdraw the causative agent in similar cases. The symptoms, onset form, and presence or absence of autoantibodies may be helpful for distinguishing between antithyroid arthritis syndrome and vasculitis, and negative results for ANCAs may help define this syndrome.
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